Clinical Trial Update: PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating GVHD prophylaxis with post-transplant cyclophosphamide plus sirolimus and VIC-1911 in myeloablative peripheral blood stem cell transp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Post-transplant cyclophosphamide (PTCy) (cyclophosphamide)
• Sirolimus (Sirolimus)
• VIC-1911

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-12-22